FDA approves next-gen Sapien valve

Candace Stuart | | Cardiovascular Business | Structural Heart Disease

The FDA has given the green light to Edwards Lifesciences to market its next-generation transcatheter aortic valve replacement (TAVR) device, the Sapien XT, for treatment in inoperable and high-risk patients with severe aortic stenosis.

The Sapien valve was the first TAVR device approved for use in the U.S. in 2011 for inoperable patients. In 2012, Edwards received the nod for its use in high-risk patients as well.

The next-generation valve and system were evaluated in the PARTNER II trial. Results presented at the American College of Cardiology scientific session in 2013 showed a lower rate of death and strokes at 30 days compared with the original Sapien valve. At 30 days, all-cause deaths were 3.5 percent for Sapien XT and 5.1 percent for the original device.

Both valves demonstrated better short-term outcomes than seen in PARTNER I, the pivotal trial for approval of Sapien.

The FDA’s approval of Sapien XT makes the 29mm valve size available for patients with large native annulus for TAVR using transfemoral and other access routes. Approval includes the NovaFlex+  transfemoral delivery system, which can use a 16-Fr expandable sheath, as well as the Ascendra+ transapical delivery systems.

Sapien XT received CE mark in Europe in 2010 and was approved in Japan in 2013.

Candace Stuart, Contributor

Related Content

How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
9 key takeaways from AHA 2024 in Chicago
Redo TAVR: The impact of implanting balloon-expandable valves in failed self-expanding valves
Edoxaban could limit blood clots, ‘make life easier’ for heart valve surgery patients

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."